Literature DB >> 28847566

Modulation of mitochondrial dysfunction and endoplasmic reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids and soluble epoxide hydrolase inhibitors.

Bora Inceoglu1, Ahmed Bettaieb2, Fawaz G Haj3, Aldrin V Gomes4, Bruce D Hammock5.   

Abstract

The arachidonic acid cascade is arguably the most widely known biologic regulatory pathway. Decades after the seminal discoveries involving its cyclooxygenase and lipoxygenase branches, studies of this cascade remain an active area of research. The third and less widely known branch, the cytochrome P450 pathway leads to highly active oxygenated lipid mediators, epoxy fatty acids (EpFAs) and hydroxyeicosatetraenoic acids (HETEs), which are of similar potency to prostanoids and leukotrienes. Unlike the COX and LOX branches, no pharmaceuticals currently are marketed targeting the P450 branch. However, data support therapeutic benefits from modulating these regulatory lipid mediators. This is being approached by stabilizing or mimicking the EpFAs or even by altering the diet. These approaches lead to predominantly beneficial effects on a wide range of apparently unrelated states resulting in an enigma of how this small group of natural chemical mediators can have such diverse effects. EpFAs are degraded by soluble epoxide hydrolase (sEH) and stabilized by inhibiting this enzyme. In this review, we focus on interconnected aspects of reported mechanisms of action of EpFAs and inhibitors of soluble epoxide hydrolase (sEHI). The sEHI and EpFAs are commonly reported to maintain homeostasis under pathological conditions while remaining neutral under normal physiological conditions. Here we provide a conceptual framework for the unique and broad range of biological activities ascribed to epoxy fatty acids. We argue that their mechanism of action pivots on their ability to prevent mitochondrial dysfunction, to reduce subsequent ROS formation and to block resulting cellular signaling cascades, primarily the endoplasmic reticulum stress. By stabilizing the mitochondrial - ROS - ER stress axis, the range of activity of EpFAs and sEHI display an overlap with the disease conditions including diabetes, fibrosis, chronic pain, cardiovascular and neurodegenerative diseases, for which the above outlined mechanisms play key roles.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arachidonic acid; Endoplasmic reticulum stress; Epoxy fatty acids; Epoxydocosapentaenoic acid; Mitochondria; Soluble epoxide hydrolase

Mesh:

Substances:

Year:  2017        PMID: 28847566      PMCID: PMC5824649          DOI: 10.1016/j.prostaglandins.2017.08.003

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  140 in total

1.  Stress-induced gene expression requires programmed recovery from translational repression.

Authors:  Isabel Novoa; Yuhong Zhang; Huiqing Zeng; Rivka Jungreis; Heather P Harding; David Ron
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

2.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

3.  Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice.

Authors:  Todd R Harris; Ahmed Bettaieb; Sean Kodani; Hua Dong; Richard Myers; Nipavan Chiamvimonvat; Fawaz G Haj; Bruce D Hammock
Journal:  Toxicol Appl Pharmacol       Date:  2015-03-28       Impact factor: 4.219

Review 4.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

5.  Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells.

Authors:  Alessandra K Cardozo; Fernanda Ortis; Joachim Storling; Ying-Mei Feng; Joanne Rasschaert; Morten Tonnesen; Françoise Van Eylen; Thomas Mandrup-Poulsen; André Herchuelz; Décio L Eizirik
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

Review 6.  Kidney CYP450 enzymes: biological actions beyond drug metabolism.

Authors:  X Zhao; J D Imig
Journal:  Curr Drug Metab       Date:  2003-02       Impact factor: 3.731

7.  4-Phenylbutyric acid reduces endoplasmic reticulum stress, trypsin activation, and acinar cell apoptosis while increasing secretion in rat pancreatic acini.

Authors:  Antje Malo; Burkhard Krüger; Burkhard Göke; Constanze H Kubisch
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

Review 8.  Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer.

Authors:  Guodong Zhang; Sean Kodani; Bruce D Hammock
Journal:  Prog Lipid Res       Date:  2013-12-15       Impact factor: 16.195

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Stereospecific activation of cardiac ATP-sensitive K(+) channels by epoxyeicosatrienoic acids: a structural determinant study.

Authors:  Tong Lu; Mike VanRollins; Hon-Chi Lee
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

View more
  28 in total

Review 1.  Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

Authors:  Jogen Atone; Karen Wagner; Kenji Hashimoto; Bruce D Hammock
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-05       Impact factor: 3.072

2.  Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.

Authors:  Qian Ren; Min Ma; Jun Yang; Risa Nonaka; Akihiro Yamaguchi; Kei-Ichi Ishikawa; Kenta Kobayashi; Shigeo Murayama; Sung Hee Hwang; Shinji Saiki; Wado Akamatsu; Nobutaka Hattori; Bruce D Hammock; Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

3.  Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model.

Authors:  Yijun Shen; Weifeng Peng; Qinglan Chen; Bruce D Hammock; Junyan Liu; Dongyang Li; Jun Yang; Jing Ding; Xin Wang
Journal:  Brain Behav Immun       Date:  2019-07-12       Impact factor: 7.217

4.  Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.

Authors:  Jan S Kramer; Stefano Woltersdorf; Thomas Duflot; Kerstin Hiesinger; Felix F Lillich; Felix Knöll; Sandra K Wittmann; Franca-M Klingler; Steffen Brunst; Apirat Chaikuad; Christophe Morisseau; Bruce D Hammock; Carola Buccellati; Angelo Sala; G Enrico Rovati; Matthieu Leuillier; Sylvain Fraineau; Julie Rondeaux; Victor Hernandez-Olmos; Jan Heering; Daniel Merk; Denys Pogoryelov; Dieter Steinhilber; Stefan Knapp; Jeremy Bellien; Ewgenij Proschak
Journal:  J Med Chem       Date:  2019-09-17       Impact factor: 7.446

5.  1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells.

Authors:  Zhibin Liang; Bei Zhang; Meng Xu; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Qing X Li
Journal:  ACS Chem Neurosci       Date:  2019-08-19       Impact factor: 4.418

6.  Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease.

Authors:  Christian Griñán-Ferré; Sandra Codony; Eugènia Pujol; Jun Yang; Rosana Leiva; Carmen Escolano; Dolors Puigoriol-Illamola; Júlia Companys-Alemany; Rubén Corpas; Coral Sanfeliu; Belen Pérez; M Isabel Loza; José Brea; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez; Mercè Pallàs; Carles Galdeano
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

7.  Soluble epoxide hydrolase inhibitor mediated analgesia lacks tolerance in rat models.

Authors:  Karen M Wagner; Jogen Atone; Bruce D Hammock
Journal:  Brain Res       Date:  2019-11-29       Impact factor: 3.252

Review 8.  Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches.

Authors:  Shashank Shekhar; Mark W Cunningham; Mallikarjuna R Pabbidi; Shaoxun Wang; George W Booz; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-20       Impact factor: 4.432

9.  N-Benzyl-linoleamide, a Constituent of Lepidium meyenii (Maca), Is an Orally Bioavailable Soluble Epoxide Hydrolase Inhibitor That Alleviates Inflammatory Pain.

Authors:  Nalin Singh; Bogdan Barnych; Christophe Morisseau; Karen M Wagner; Debin Wan; Ashley Takeshita; Hoang Pham; Ting Xu; Abhaya Dandekar; Jun-Yan Liu; Bruce D Hammock
Journal:  J Nat Prod       Date:  2020-12-15       Impact factor: 4.050

10.  EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence.

Authors:  Jeremie Gautheron; Christophe Morisseau; Wendy K Chung; Jamila Zammouri; Martine Auclair; Genevieve Baujat; Emilie Capel; Celia Moulin; Yuxin Wang; Jun Yang; Bruce D Hammock; Barbara Cerame; Franck Phan; Bruno Fève; Corinne Vigouroux; Fabrizio Andreelli; Isabelle Jeru
Journal:  Elife       Date:  2021-08-03       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.